ADVANCED LUNG NON-SMALL CELL CARCINOMA
Clinical trials for ADVANCED LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to boost immune system against tough lung cancer
Disease control OngoingThis study tests whether adding an experimental drug (N-803) to the immunotherapy pembrolizumab works better than standard treatments for people with advanced non-small cell lung cancer that has already been treated with other immunotherapies. N-803 activates natural killer cells…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 26, 2026 12:06 UTC
-
New combo therapy targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially bladder cancer. The main goals are to find the safest dose and understand side effects. About 7…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 12:05 UTC
-
New drug cocktail targets Hard-to-Treat lung cancer
Disease control OngoingThis early-phase study tests a new combination of two drugs, minnelide and osimertinib, for people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). The main goal is to find the safest dose and see how the body responds. Only 8 participants…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 12:04 UTC
-
Cord blood cells engineered to fight lung cancer in early trial
Disease control OngoingThis early-phase study tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment uses immune cells from donated umbilical cord blood that are genetically modified to better recognize and attack cance…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New drug combo aims to halt lung cancer growth
Disease control OngoingThis study tests a new combination of two drugs, osimertinib and telaglenastat, in people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. The goal is to find the safest dose and see how well the drugs work together to stop cancer cells from growin…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC